[Market Movement Analysis] Daily Target 2x Long MRNA Soars on September 17: Cancer Vaccine Success + mRNA + Leverage
Bitget异动解读2026/09/17 13:501. On August 19, Moderna and Merck announced that the Phase III trial of the personalized mRNA therapy Intismeran combined with Pembrolizumab for treating high-risk melanoma reached its primary and key secondary endpoints, with no new safety risks identified.
2. As of March 31, the company owns three commercial products: Spikevax, mNEXSPIKE, and mRESVIA. It is also advancing vaccines for infectious diseases, oncology treatments, and rare disease therapies, with a development pipeline comprising 25 candidate projects.
3. On September 10, the options trading volume for Moderna reached 104,700 contracts, with call options accounting for 72.3%. Open interest was about 932,200 contracts, equivalent to 115.46% of the 30-day moving average; MRNX is the daily target 2x long Moderna product, where underlying volatility is amplified by daily leverage.
(Disclaimer: This content is summarized by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
When the river warms, the ducks are the first to know! Wall Street issues a warning: "The trading frenzy" is losing momentum
The Wall Street trading feast coming to an end? The share price of Bank of America plunged by 5% in a single day after its CEO described performance as "flat," dragging peers lower as well. After the combined stock trading revenue of the Big Four banks soared by 72% to a record high in Q2, executives have made the rare move of collectively lowering their outlook for Q3. The "extraordinary quarter" driven by the AI boom, speculative trading in Asian semiconductors, and the massive SpaceX IPO is unlikely to be repeated.
Crypto prices
More
